ECSP22030119A - DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONInfo
- Publication number
- ECSP22030119A ECSP22030119A ECSENADI202230119A ECDI202230119A ECSP22030119A EC SP22030119 A ECSP22030119 A EC SP22030119A EC SENADI202230119 A ECSENADI202230119 A EC SENADI202230119A EC DI202230119 A ECDI202230119 A EC DI202230119A EC SP22030119 A ECSP22030119 A EC SP22030119A
- Authority
- EC
- Ecuador
- Prior art keywords
- dosage forms
- bupropion
- enantiomerically enriched
- methods
- pure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Esta divulgación se refiere a las formas de dosificación que contienen un bupropión enantioméricamente enriquecido o puro, tal como un exceso enantiomérico del (S)-bupropión, del (S)-bupropión enantioméricamente enriquecido o del (S)-bupropión enantioméricamente puro, y a los métodos de uso de estas formas de dosificación. Estas formas de dosificación se pueden administrar a los seres humanos en una cantidad reducida en comparación con la cantidad de bupropión racémico que se administraría en la misma situación.This disclosure relates to dosage forms containing enantiomerically enriched or pure bupropion, such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion, and to methods of using these dosage forms. These dosage forms can be administered to humans in a reduced amount compared to the amount of racemic bupropion that would be administered in the same situation.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/052210 WO2020061486A2 (en) | 2018-09-20 | 2019-09-20 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US202062971174P | 2020-02-06 | 2020-02-06 | |
| US202062978626P | 2020-02-19 | 2020-02-19 | |
| US202062992060P | 2020-03-19 | 2020-03-19 | |
| US16/830,637 US20200222339A1 (en) | 2018-09-20 | 2020-03-26 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US16/907,691 US11433035B2 (en) | 2018-09-20 | 2020-06-22 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22030119A true ECSP22030119A (en) | 2022-05-31 |
Family
ID=74884634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202230119A ECSP22030119A (en) | 2019-09-20 | 2022-04-13 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4031121A4 (en) |
| JP (2) | JP2022549192A (en) |
| KR (1) | KR20220066930A (en) |
| CN (1) | CN114423417A (en) |
| AU (3) | AU2020349419B2 (en) |
| BR (1) | BR112022005045A2 (en) |
| CA (2) | CA3154718C (en) |
| CO (1) | CO2022003126A2 (en) |
| CR (1) | CR20220119A (en) |
| EC (1) | ECSP22030119A (en) |
| IL (1) | IL291514A (en) |
| MX (1) | MX2022003346A (en) |
| NZ (1) | NZ786429A2 (en) |
| PE (1) | PE20221314A1 (en) |
| WO (1) | WO2021055124A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021055124A1 (en) * | 2019-09-20 | 2021-03-25 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051166A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+) -bupropion |
| US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
| US20190216800A1 (en) * | 2013-11-05 | 2019-07-18 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2013014166A (en) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Active enantiomers and the salts thereof for treating obesity. |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| IL276871B2 (en) * | 2018-02-23 | 2024-11-01 | Axsome Therapeutics Inc | Pure bupropion dosage forms and methods for enantiomeric distortion purposes |
| WO2021055124A1 (en) * | 2019-09-20 | 2021-03-25 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2020
- 2020-08-18 WO PCT/US2020/046755 patent/WO2021055124A1/en not_active Ceased
- 2020-08-18 CR CR20220119A patent/CR20220119A/en unknown
- 2020-08-18 CN CN202080065520.4A patent/CN114423417A/en active Pending
- 2020-08-18 AU AU2020349419A patent/AU2020349419B2/en active Active
- 2020-08-18 CA CA3154718A patent/CA3154718C/en active Active
- 2020-08-18 KR KR1020227013095A patent/KR20220066930A/en active Pending
- 2020-08-18 MX MX2022003346A patent/MX2022003346A/en unknown
- 2020-08-18 PE PE2022000441A patent/PE20221314A1/en unknown
- 2020-08-18 NZ NZ786429A patent/NZ786429A2/en active IP Right Revival
- 2020-08-18 EP EP20866164.5A patent/EP4031121A4/en active Pending
- 2020-08-18 BR BR112022005045A patent/BR112022005045A2/en unknown
- 2020-08-18 JP JP2022517743A patent/JP2022549192A/en active Pending
- 2020-08-18 CA CA3287347A patent/CA3287347A1/en active Pending
-
2022
- 2022-03-18 CO CONC2022/0003126A patent/CO2022003126A2/en unknown
- 2022-03-20 IL IL291514A patent/IL291514A/en unknown
- 2022-04-13 EC ECSENADI202230119A patent/ECSP22030119A/en unknown
-
2024
- 2024-01-05 AU AU2024200081A patent/AU2024200081B2/en active Active
- 2024-02-22 JP JP2024025971A patent/JP2024059812A/en active Pending
-
2026
- 2026-02-25 AU AU2026201399A patent/AU2026201399A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020349419A1 (en) | 2022-03-24 |
| MX2022003346A (en) | 2022-04-11 |
| KR20220066930A (en) | 2022-05-24 |
| IL291514A (en) | 2022-05-01 |
| NZ786429A (en) | 2025-08-29 |
| CR20220119A (en) | 2022-06-22 |
| WO2021055124A1 (en) | 2021-03-25 |
| CA3287347A1 (en) | 2025-11-29 |
| CA3154718A1 (en) | 2021-03-25 |
| CN114423417A (en) | 2022-04-29 |
| PE20221314A1 (en) | 2022-09-07 |
| AU2024200081A1 (en) | 2024-01-25 |
| AU2024200081B2 (en) | 2025-11-27 |
| EP4031121A1 (en) | 2022-07-27 |
| AU2020349419B2 (en) | 2023-11-02 |
| JP2022549192A (en) | 2022-11-24 |
| EP4031121A4 (en) | 2022-11-30 |
| NZ786429A2 (en) | 2026-01-30 |
| CA3154718C (en) | 2026-02-24 |
| JP2024059812A (en) | 2024-05-01 |
| BR112022005045A2 (en) | 2022-07-05 |
| CO2022003126A2 (en) | 2022-04-19 |
| AU2026201399A1 (en) | 2026-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000075A1 (en) | Agents, uses and methods for the treatment of synucleinopathy. | |
| MX2020000734A (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same. | |
| CL2020002166A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion. | |
| CL2019001293A1 (en) | Agents, uses and methods for the treatment of synucleinopathy. | |
| DOP2019000040A (en) | SUBSTITUTED PIRROLIZINE COMPOUNDS AND USES OF THE SAME | |
| CO2019009258A2 (en) | Fast and controlled administration of compositions with restored entourage effects | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| MX375286B (en) | Spiro-lactam NMDA receptor modulators and their uses. | |
| CL2019000248A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
| CL2019000247A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof. | |
| CO2019011265A2 (en) | Modulators of Pcsk9 Expression | |
| AR105894A1 (en) | COMPOSITION FOR TOPICAL APPLICATION THAT INCLUDES ISOSORBID DIMETHYL, A POLYOL, AND A PHENOLIC OR POLYPHENOLIC ANTIOXIDANT | |
| MX394318B (en) | Pyrazole magl inhibitors | |
| ECSP22030119A (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| MX2018006005A (en) | Formulations comprising oxalate salts of teneligliptin and solvates thereof. | |
| UY37261A (en) | COMBINED FORMULATION OF THREE ANTIVIRAL COMPOUNDS | |
| MX2021008303A (en) | LTA4H INHIBITORS FOR THE TREATMENT OF HYDRADENITIS SUPPURATIVA. | |
| DOP2018000211A (en) | COMPOSITIONS AND METHODS TO STABILIZE ALFAVIRUS WITH IMPROVED FORMULATIONS | |
| MY198747A (en) | Composition for external use | |
| HK40068404A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CO2020009271A2 (en) | Compounds that can be used as a tumor inhibitor, method of their preparation and their application | |
| BR112021011755A8 (en) | METHOD TO PROVIDE AN ORAL TREATMENT BENEFIT WITH THE USE OF A LOW SOLUBILITY CALCIUM AND FLUORIDE COMPOUND | |
| HK40041795A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CO2016001336A1 (en) | Method and composition and kit to treat erectile dysfunction |